{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115344","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.725859+00:00","generated_at":"2026-05-30T03:17:23.812640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cryoport Q3 revenue flat YoY at $56.7M; services up 9%, product down 14%","bullets":["Net loss attributable to common stockholders: $1.2M ($0.02/share) vs $15.3M loss ($0.31) YoY.","Life Sciences Services revenue up 9% to $39.3M; gross margin improved to 46%.","Life Sciences Products revenue down 14% to $17.4M; total gross margin 44.8%.","Full-year 2024 revenue guidance reaffirmed at $225-235M; management targets positive adjusted EBITDA in 2025.","Repurchased $175M principal of 2026 convertible notes for $154.5M; cash and short-term investments $272.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115344","json":"https://secwatch.observer/filing/0001104659-24-115344.json","markdown":"https://secwatch.observer/filing/0001104659-24-115344.md","text":"https://secwatch.observer/filing/0001104659-24-115344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465924115344/0001104659-24-115344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465924115344/tm2427809d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:17:23.812640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}